SE328670B - - Google Patents

Info

Publication number
SE328670B
SE328670B SE12477/63A SE1247763A SE328670B SE 328670 B SE328670 B SE 328670B SE 12477/63 A SE12477/63 A SE 12477/63A SE 1247763 A SE1247763 A SE 1247763A SE 328670 B SE328670 B SE 328670B
Authority
SE
Sweden
Application number
SE12477/63A
Inventor
K Heimlich
D Macdonnell
Original Assignee
Smith Kline French Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline French Lab filed Critical Smith Kline French Lab
Publication of SE328670B publication Critical patent/SE328670B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE12477/63A 1962-12-19 1963-11-12 SE328670B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US245681A US3119742A (en) 1962-12-19 1962-12-19 Method of preparing sustained release pharmaceutical pellets and product thereof

Publications (1)

Publication Number Publication Date
SE328670B true SE328670B (OSRAM) 1970-09-21

Family

ID=22927638

Family Applications (1)

Application Number Title Priority Date Filing Date
SE12477/63A SE328670B (OSRAM) 1962-12-19 1963-11-12

Country Status (5)

Country Link
US (1) US3119742A (OSRAM)
BE (1) BE640616A (OSRAM)
GB (1) GB1030127A (OSRAM)
IT (1) IT983055B (OSRAM)
SE (1) SE328670B (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007870A1 (en) * 1987-04-09 1988-10-20 Carbomatrix Ab A method for entrapment of biologically active substances and the use thereof

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) * 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
US4421736A (en) * 1982-05-20 1983-12-20 Merrel Dow Pharmaceuticals Inc. Sustained release diethylpropion compositions
US4507276A (en) * 1982-08-20 1985-03-26 Bristol-Myers Company Analgesic capsule
FR2548021B1 (fr) * 1983-06-29 1986-02-28 Dick P R Compositions pharmaceutiques dermiques a action prolongee et continue a base d'acides gras essentiels
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.
US4755387A (en) * 1985-03-21 1988-07-05 The Procter & Gamble Company Therapeutic particles
US4874614A (en) * 1985-03-25 1989-10-17 Abbott Laboratories Pharmaceutical tableting method
US4863741A (en) * 1985-03-25 1989-09-05 Abbott Laboratories Tablet composition for drug combinations
CA1279574C (en) * 1985-04-17 1991-01-29 Jeffrey L. Finnan Process for lubricating water-soluble vitamin powders
US4728512A (en) * 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) * 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US4904476A (en) * 1986-03-04 1990-02-27 American Home Products Corporation Formulations providing three distinct releases
US5019302A (en) * 1986-03-12 1991-05-28 Washington University Technology Associates, Inc. Method for granulation
FI77573C (fi) * 1987-05-08 1989-04-10 Orion Yhtymae Oy Ny konsistens.
JP2668880B2 (ja) * 1987-06-23 1997-10-27 日本油脂株式会社 被覆アミノ酸類の製造方法
DE3721721C1 (de) * 1987-07-01 1988-06-09 Hoechst Ag Verfahren zur Umhuellung von Granulaten
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5328697A (en) * 1992-02-10 1994-07-12 Mallinckrodt Veterinary, Inc. Compositions and processes for the sustained release of drugs
NZ518884A (en) 1999-12-10 2004-02-27 Pfizer Prod Inc Pyrrolo[2,3-d]pyrimidine compounds
US6544555B2 (en) * 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
SK13652002A3 (sk) * 2000-03-31 2004-01-08 Pfizer Products Inc. Deriváty piperazínu
US20020068078A1 (en) * 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
BR0114697A (pt) * 2000-10-19 2003-11-18 Pfizer Prod Inc Derivados em ponte de piperazina
KR20040012956A (ko) * 2001-06-20 2004-02-11 화이자 프로덕츠 인코포레이티드 설폰산 유도체
PL370548A1 (en) * 2001-10-22 2005-05-30 Pfizer Products Inc. Piperazine derivatives with ccr1 receptor antagonist activity
CA2484342A1 (en) * 2002-05-14 2003-11-20 Pfizer Products Inc. Methods for manufacture of dihydro-furan-2-one derivatives
PL373961A1 (en) * 2002-05-14 2005-09-19 Pfizer Products Inc. Dihydroxyhexanoic acid derivatives, their intermediates, and methods of making
PA8575901A1 (es) * 2002-07-18 2004-07-20 Pfizer Prod Inc Derivados de piperidina novedosos
BR0313378A (pt) * 2002-08-12 2005-07-12 Pfizer Producs Inc Formas cristalinas da [4carbamoil-1-(3-fluorobenzil)-2,7-dihidróxi-7-metil-o ctil]-amida do ácido quinoxalina-2-carboxìlico
EA200500377A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
US20040097554A1 (en) * 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
US20040116441A1 (en) * 2002-10-30 2004-06-17 Pfizer Inc Methods of using sulfonic acid derivatives
US20040087571A1 (en) * 2002-10-30 2004-05-06 Pfizer Inc Methods of using CCR1 antagonists as immunomodulatory agents
RS20050380A (sr) * 2002-11-21 2007-11-15 Pfizer Products Inc., Derivati 3-aminopiperidina i postupci njihove proizvodnje
MXPA05005576A (es) * 2002-11-26 2005-07-27 Pfizer Prod Inc Procedimiento de tratamiento del rechazo a un trasplante.
MXPA05006229A (es) * 2002-12-13 2005-08-19 Pfizer Prod Inc Derivados de piperazina que contienen fosforo como antagonistas de ccr1.
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
MXPA05008568A (es) * 2003-02-14 2005-11-04 Pfizer Prod Inc Nuevos compuestos anti-inflamatorios triazolo-piridinas.
PA8595001A1 (es) * 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
EP1606267B1 (en) * 2003-03-11 2008-07-30 Pfizer Products Inc. Pyrazine compounds as transforming growth factor (tgf) inhibitors
US20050119275A1 (en) * 2003-06-24 2005-06-02 Pfizer Inc. Salt and crystal forms of (5-chloro-2-{2-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy}-phenyl)-methanesulfonic acid
WO2005051393A1 (en) * 2003-11-25 2005-06-09 Pfizer Products Inc. Method of treatment of atherosclerosis
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
US8461102B2 (en) * 2010-03-02 2013-06-11 George E. Royster, JR. Methods and compositions for treating and preventing symptoms of hormonal variations
PT2685986T (pt) 2011-03-18 2020-03-05 Genzyme Corp Inibidor de glicosilceramida-sintase
MX365242B (es) 2011-05-16 2019-05-28 Genzyme Corp El uso del antagonista cxcr4: 1,1´-[1,4-fenileno-bis-(metileno)-bi s-1, 4, 8, 11-tetraazaciclotetradecano (plerixaflor) para el tratamiento del síndrome de whim.
WO2013037065A1 (en) 2011-09-13 2013-03-21 Ottawa Hospital Research Institute Microrna inhibitors
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
WO2014160401A1 (en) 2013-03-13 2014-10-02 Boston Biomedical, Inc. 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
EP3060234A1 (en) 2013-10-24 2016-08-31 AbbVie Inc. Jak1 selective inhibitor and uses thereof
US10065937B2 (en) 2014-07-31 2018-09-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) FLT3 receptor antagonists
MA41202A (fr) 2014-12-18 2017-10-24 Genzyme Corp Copolymères polydiallymine réticulé pour le traitement du diabète de type 2
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
KR20250010141A (ko) 2015-10-16 2025-01-20 애브비 인코포레이티드 (3S,4R)-3-에틸-4-(3H-이미다조[1,2-a]피롤로[2,3-e]-피라진-8-일)-N-(2,2,2-트리플루오로에틸)피롤리딘-1-카복스아미드및 이의 고체상 형태의 제조 방법
US12365689B2 (en) 2015-10-16 2025-07-22 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US20200181089A1 (en) 2016-07-08 2020-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) 4-anilino-quinoline compounds as anti-cancer agents
AU2019205595B2 (en) 2018-01-05 2023-01-05 Centre Hospitalier Universitaire De Nice Substituted halo-quinoline derivatives, method of preparation and applications thereof
CN113330007A (zh) 2018-10-03 2021-08-31 特沙诺有限公司 尼拉帕利游离碱的晶体形式
WO2020072797A1 (en) 2018-10-03 2020-04-09 Tesaro, Inc. Niraparib salts
JP7511567B2 (ja) 2019-02-04 2024-07-05 ジェンザイム・コーポレーション リソソーム蓄積性疾患と関連する症状および障害を処置するための方法
JP7633169B2 (ja) 2019-02-04 2025-02-19 ジェンザイム・コーポレーション グルコシルセラミドシンターゼ（ｇｃｓ）阻害剤を使用した繊毛病の処置
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
BR112023000798A2 (pt) 2020-07-24 2023-02-07 Genzyme Corp Composições farmacêuticas compreendendo venglustat
WO2022072397A1 (en) 2020-09-30 2022-04-07 Bioverativ Therapeutics Inc. Ampk activators and methods of use thereof
WO2022140528A1 (en) 2020-12-23 2022-06-30 Genzyme Corporation Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
WO2023196640A1 (en) 2022-04-08 2023-10-12 Bioverativ Therapeutics Inc. Oxindole derivatives as ampk activators for use in the treatment of rare blood disorders
AU2023403087A1 (en) 2022-12-01 2025-07-17 Genzyme Corporation Venglustat in combination with a strong or moderate inhibitor of cyp3a4
WO2025074120A1 (en) 2023-10-06 2025-04-10 Imperial College Innovations Limited Nanoparticles for extended release drug delivery
WO2025262570A1 (en) 2024-06-17 2025-12-26 Genzyme Corporation Venglustat as an inhibitor of glucosylceramide synthase in subjects having hepatic impairment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US2793979A (en) * 1953-03-30 1957-05-28 Smith Kline French Lab Method of making a sustained release pharmaceutical tablet and product of the method
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007870A1 (en) * 1987-04-09 1988-10-20 Carbomatrix Ab A method for entrapment of biologically active substances and the use thereof

Also Published As

Publication number Publication date
US3119742A (en) 1964-01-28
DE1492128A1 (de) 1969-08-07
IT983055B (it) 1974-10-31
GB1030127A (en) 1966-05-18
BE640616A (OSRAM)

Similar Documents

Publication Publication Date Title
BE616548R (OSRAM)
BE631916A (OSRAM)
BE604335A (OSRAM)
BE380301A (OSRAM)
BE489310A (OSRAM)
BE538252A (OSRAM)
BE538831A (OSRAM)
BE541929A (OSRAM)
BE553896A (OSRAM)
BE559145A (OSRAM)
BE586180A (OSRAM)
BE592434A (OSRAM)
BE599783A (OSRAM)
BE631672A (OSRAM)
BE608197A (OSRAM)
BE609543A (OSRAM)
BE612190A (OSRAM)
BE612311A (OSRAM)
BE612464A (OSRAM)
BE612847A (OSRAM)
BE612926A (OSRAM)
BE613108A (OSRAM)
BE613190A (OSRAM)
BE613298A (OSRAM)
BE613319A (OSRAM)